Status:
COMPLETED
Small Changes Behavioural Weight Loss Treatment Approach for Psoriatic Arthritis Patients With Comorbid Obesity
Lead Sponsor:
University of Calgary
Conditions:
Psoriatic Arthritis
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Psoriatic Arthritis (PsA) is a type of auto-immune condition that affects roughly 90,000 Canadians. Patients with PsA often experience joint pain, skin problems, and issues with mobility that negative...
Detailed Description
Background: Psoriatic Arthritis (PsA) is an inflammatory auto-immune disorder that impacts approximately 3-in-10 patients with skin psoriasis. Compared to other rheumatologic conditions, patients with...
Eligibility Criteria
Inclusion
- 18+ years old,
- new or previous diagnosis of symptomatic psoriatic arthritis
- BMI ≥30kg/m2),
- willing to participate in a BWLT program,
- can speak and write in English to complete surveys,
- able to participate in virtual Zoom meetings (I.e., access to a computer with email, internet and a webcam)
Exclusion
- unstable ischemic cardiovascular disease
- severe pulmonary disease
- currently pregnant or breastfeeding
- active substance use disorder (drug or alcohol),
- currently participating in another structured weight-loss program
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 22 2023
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT05225623
Start Date
February 1 2022
End Date
September 22 2023
Last Update
December 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Behavioural Medicine Laboratory
Calgary, Alberta, Canada, T2N 1N4